- Home
- YCY vs QSI Comparison
YCY vs QSI Comparison
Compare YCY & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YCY | QSI |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 165.6M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | YCY | QSI |
|---|---|---|
| Price | $10.23 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 46.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,436,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $618.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.90 | $0.69 |
| 52 Week High | $10.28 | $3.10 |
Technical Indicators
Market Signals| Indicator | YCY | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 47.93 |
| Support Level | $9.95 | $0.70 |
| Resistance Level | $10.24 | $0.79 |
| Average True Range (ATR) | 0.01 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 44.17 |
Price Performance
Historical ComparisonAbout YCY AA Mission Acquisition Corp. II Class A Ordinary Shares
AA Mission Acquisition Corp II is a blank check company formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.